NCT01358877 · MORE INFO

Limitations, agreements, and source contact

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer · Source last updated 2025-11-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: genentech@druginfo.com
organization: Hoffmann-La Roche
phone: 800-821-8590
title: Medical Communications

Complete source fields

certain Agreement

other Details: The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: genentech@druginfo.com
organization: Hoffmann-La Roche
phone: 800-821-8590
title: Medical Communications

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice